RxDoctor Payments Data

Adam McDonough, MD

Psychiatry · Winston Salem, NCNPI 1225349053

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $61,668 of the $68,975 with a category attached, or 89.4%. AbbVie accounts for 71.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $42,852 and has fallen 99.9% since, to $35 in 2024. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,975in general payments, 2019–2025

Across 173 payments — averaging $398.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$49K
  • Alkermes, Inc.$14K
  • Otsuka America Pharmaceutical, Inc.$4K
  • Johnson & Johnson$469
  • Teva Pharmaceuticals USA, Inc.$208
  • Sunovion Pharmaceuticals Inc.$185
  • plus $151 from 4 others

What the payments were for

  • Speaking & faculty fees$61,66889%
  • Travel & lodging$3,5655%
  • Food & beverage$3,7245%
  • Education$180%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,975 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,016
Medicare patients
21
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate15$42,707
VraylarCariprazine Hcl19$27,398
Ramelteon12$2,029
Paliperidone ErPaliperidone18$1,921
Fluphenazine Decanoate12$1,461
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,280
Fluvoxamine Maleate13$1,056
Olanzapine17$1,054
Quetiapine Fumarate ErQuetiapine Fumarate23$1,036
Venlafaxine Hcl ErVenlafaxine Hcl42$892
Duloxetine Hcl19$729
AmantadineAmantadine Hcl12$715
Lamotrigine49$700
Fluoxetine Hcl38$670
Aripiprazole38$652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$469$42,70715 claims
AbbVieVraylar$49,062$27,39819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →